DESTINY-PANTUMOUR04
Part of paid clinical trials in Birmingham, Alabama.
- Sponsor
- AstraZeneca
- Study ID
- NCT07124000
- Status
- Recruiting
Conditions
- Adenocarcinoma (NOS)
- Anal Cancer
- Bladder Cancer
- Cervical Cancer
- Endometrial Cancer
- Esophageal Cancer
- Gall Bladder Cancer
- Gastrointestinal Stromal Tumour
- Head and Neck Cancer
- Liver Cancer
- Melanoma
- Mouth Cancer
- Nasopharangeal Cancer
- Neuroendocrine, Gastrointestinal Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Prostate Cancer
- Renal Cell Carcinoma
- Salivary Gland Cancer
- Sarcoma
- Small Cell Lung Cancer
- Testicular Cancer
- Throat Cancer
- Thyroid Cancer
- Urethral Cancer
- Vaginal Cancer
- Vulvar Cancer
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 130 Years
- Healthy Volunteers
- Not accepted
Interventions
- Trastuzumab deruxtecan — DRUGTrastuzumab deruxtecan monotherapy
Study Details
This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world setting in the US
Key Dates
- First listed
- Aug 15, 2025
- Start date
- Sep 18, 2025
- Status verified
- Aug 2026
- Primary completion
- Mar 30, 2028
- Completion
- Mar 30, 2028
Study Design
- Enrollment
- 100 participants (estimated)
Arms
- Arm: Trastuzumab deruxtecanPatients with locally advanced, unresectable, or metastatic HER-2 positive (IHC3+) solid tumours for whom a clinician decision has been made for treatment with T-DXd as part of routine clinical practice and in line with the FDA label
Primary Outcome Measure
Real world response rate (rwRR) [ Time Frame: Through study completion, up to 2.5 years after enrolment ]
Central Contacts
- AstraZeneca Clinical Study Information Center1-877-240-9479
Locations (18)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | 35243 | - |
| Research Site | Bullhead City | Arizona | 86442 | - |
| Research Site | Casa Grande | Arizona | 85122 | - |
| Research Site | San Diego | California | 92123 | - |
| Research Site | Boulder | Colorado | 80309 | - |
| Research Site | Coral Springs | Florida | 33065 | - |
| Research Site | St. Petersburg | Florida | 33714 | - |
| Research Site | West Palm Beach | Florida | 33401 | - |
| Research Site | Decatur | Illinois | 62526 | - |
| Research Site | Topeka | Kansas | 66604 | - |
| Research Site | Farmington | New Mexico | 87401 | - |
| Research Site | Durham | North Carolina | 27708 | - |
| Research Site | Wilson | North Carolina | 27893 | - |
| Research Site | Canton | Ohio | 44718 | - |
| Research Site | Maumee | Ohio | 43537 | - |
| Research Site | Philadelphia | Pennsylvania | 19104 | - |
| Research Site | Nashville | Tennessee | 37203 | - |
| Research Site | Dallas | Texas | 75390 | - |
Find similar trials in Birmingham, AL
Nationwide
Bladder cancer trialsCervical cancer trialsEndometrial cancer trialsEsophageal cancer trialsHead and neck cancer trialsLiver cancer trialsMelanoma trialsOvarian cancer trialsPancreatic cancer trialsProstate cancer trialsKidney cancer trialsLung cancer trialsOncology trialsUrology trialsGynecologic oncology trialsWomen's health trialsGI oncology trialsENT trialsHepatology trialsSkin cancer trialsDermatology trialsProstate oncology trialsMen's health trialsLung oncology trialsLung disease trials
By condition
Related Studies
- Specimen and Data Study for Ovarian Cancer Early Detection and PreventionRecruiting · Northwestern University · Chicago, Illinois
- Identification and Characterization of Novel Proteins and Genes in Head and Neck CancerRecruiting · Stanford University · Stanford, California
- Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of LifeRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
- Esophageal Cancer Risk RegistryRecruiting · University of Pittsburgh · Pittsburgh, Pennsylvania